|
DOPEY2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.50399999623951E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.71029999945982E-07 |
| Normal-vs-Stage2 |
2.096500E-02 |
| Normal-vs-Stage3 |
2.32799999999589E-06 |
| Normal-vs-Stage4 |
6.1372000000004E-05 |
| Stage1-vs-Stage2 |
4.586600E-01 |
| Stage1-vs-Stage3 |
4.956400E-01 |
| Stage1-vs-Stage4 |
2.694400E-01 |
| Stage2-vs-Stage3 |
2.813600E-01 |
| Stage2-vs-Stage4 |
1.830780E-01 |
| Stage3-vs-Stage4 |
6.074000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.92749999797337E-08 |
| Normal-vs-AfricanAmerican |
8.775500E-04 |
| Normal-vs-Asian |
6.196900E-03 |
| Caucasian-vs-AfricanAmerican |
3.592200E-01 |
| Caucasian-vs-Asian |
3.874800E-01 |
| AfricanAmerican-vs-Asian |
1.641630E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.368500E-04 |
| Normal-vs-Female |
5.53449996942845E-09 |
| Male-vs-Female |
7.104500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.29969999995705E-06 |
| Normal-vs-Age(41-60Yrs) |
2.37000000002929E-06 |
| Normal-vs-Age(61-80Yrs) |
1.04170000003734E-06 |
| Normal-vs-Age(81-100Yrs) |
7.051600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.902600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.683600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.590960E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.587780E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.753970E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.066850E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.248400E-02 |
| Classical-VS-Follicular |
2.35379999999896E-05 |
| Classical-VS-Other |
4.962200E-02 |
| Classical-VS-Normal |
3.92409993388299E-10 |
| Tall-VS-Follicular |
5.58819999999516E-05 |
| Tall-VS-Other |
9.402300E-03 |
| Tall-VS-Normal |
1.06899999996468E-06 |
| Follicular-VS-Other |
5.556400E-01 |
| Follicular-VS-Normal |
1.691440E-01 |
| Other-VS-Normal |
9.422800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.65440000000317E-05 |
| Normal-vs-N1 |
2.335600E-02 |
| N0-vs-N1 |
6.821800E-01 |
|
|
